

## DAFTAR PUSTAKA

- Ando, M., Hamajima, N., Ariyoshi, N., Kamataki, T., Matsuo, K., dan Ohno, Y., 2003. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. *Journal of Epidemiology*, **13**: 176–181.
- Arab-Alameddine, M., Di Iulio, J., Buclin, T., Rotger, M., Lubomirov, R., Cavassini, M., dkk., 2009. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. *Clinical Pharmacology and Therapeutics*, **85**: 485–494.
- Ariyoshi, N., Miyamoto, M., Umetsu, Y., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y.-I., dkk., 2002. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. *Cancer Epidemiology, Biomarkers & Prevention*, **11**: 890–894.
- Ariyoshi, N., Takahashi, Y., Miyamoto, M., Umetsu, Y., Daigo, S., Tateishi, T., dkk., 2000. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6\*1B) apparently diagnosed as heterozygotes of CYP2A6\*1A and CYP2A6\*4C. *Pharmacogenetics*, **10**: 687–693.
- Armitage, A.K., Dollery, C.T., George, C.F., Houseman, T.H., Lewis, P.J., dan Turner, D.M., 1975. Absorption and metabolism of nicotine from cigarettes. *British Medical Journal*, **4**: 313–316.
- Badran, E., Salhab, A.S., dan Al-Jaghbir, M., 2009. Infant exposure to environmental tobacco smoke: Jordan University hospital-based study. *Eastern Mediterranean Health Journal*, **15**: 39–46.
- Banyasz, J.L., 1999. Chapter 5 - The physical chemistry of nicotine, dalam: Jacob, J.W.G. (Editor), *Analytical Determination of Nicotine and Related Compounds and Their Metabolites*. Elsevier Science, Amsterdam, hal. 149–190.
- Bao, Z., He, X.-Y., Ding, X., Prabhu, S., dan Hong, J.-Y., 2005. Metabolism of Nicotine and Cotinine by Human Cytochrome P450 2a13. *Drug Metabolism and Disposition*, **33**: 258–261.
- Barber, S., Adioetomo, S.M., Ahsan, A., dan Setyonaluri, D., 2008. *Tobacco Economics in Indonesia*. International Union Against, Paris, hal 1-4.



- Baumann, F., Regenthal, R., Burgos-Guerrero, I.L., Hegerl, U., dan Preiss, R., 2010. Determination of nicotine and cotinine in human serum by means of LC/MS. *Journal of Chromatography B*, **878**: 107–111.
- Behera, D., Uppal, R., dan Majumdar, S., 2003. Urinary levels of nicotine & cotinine in tobacco users. *The Indian Journal of Medical Research*, **118**: 129–133.
- Benowitz, N.L., 1990. Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence. *NIDA Research Monograph*, **99**: 12–29.
- Benowitz, N.L., 1996. Cotinine as a biomarker of environmental tobacco smoke exposure. *Epidemiologic Reviews*, **18**: 188–204.
- Benowitz, N.L., 2010. Nicotine addiction. *The New England Journal of Medicine*, **362**: 2295–2303.
- Benowitz, N.L., Hukkanen, J., dan Jacob, P., 2009. Nicotine Chemistry, Metabolism, Kinetics and Biomarkers. *Handbook of Experimental Pharmacology*, 29–60.
- Benowitz, N.L., Hukkanen, J., dan Jacob, P., 3rd, 2009. Nicotine chemistry, metabolism, kinetics and biomarkers. *Handbook of Experimental Pharmacology*, 29–60.
- Benowitz, N.L. dan Jacob, P., 2001. Trans-3'-hydroxycotinine: Disposition kinetics, effects and plasma levels during cigarette smoking. *British Journal of Clinical Pharmacology*, **51**: 53–59.
- Benowitz, N.L., Perez-Stable, E.J., Fong, I., Modin, G., Herrera, B., dan Jacob, P., 3rd, 1999. Ethnic differences in N-glucuronidation of nicotine and cotinine. *The Journal of Pharmacology and Experimental Therapeutics*, **291**: 1196–1203.
- Benowitz, N.L., Pomerleau, O.F., Pomerleau, C.S., dan Jacob, P., 3rd, 2003. Nicotine metabolite ratio as a predictor of cigarette consumption. *Nicotine & Tobacco Research*, **5**: 621–624.
- Bhalala, O., 2003. Detection of Cotinine in Blood Plasma by HPLC MS/MS. *MIT Undergraduate Research Journal*, **8**: 45–50.
- Bhatnagar, A.S., 2007. The discovery and mechanism of action of letrozole. *Breast Cancer Research and Treatment*, **105**: 7–17.



- Boardman, J.D., Blalock, C.L., Pampel, F.C., Hatemi, P.K., Heath, A.C., dan Eaves, L.J., 2011. Population Composition, Public Policy, and the Genetics of Smoking. *Demography*, **48**: 1517–1533.
- Boffetta, P., Hecht, S., Gray, N., Gupta, P., dan Straif, K., 2008. Smokeless tobacco and cancer. *The Lancet Oncology*, **9**: 667–675.
- Boyle, P., Gray, N., Henningfield, J., Seffrin, J., Zatonski, W., 2010. *Tobacco: Science, Policy and Public Health*. Oxford University Press, hal. 287-307.
- Badan Pusat Statistik, 2010. *Sensus Penduduk 2010 - Indonesia*, diakses tanggal 19 Januari 2015. < <http://sp2010.bps.go.id/>>.
- B-Rao, C., 2001. Sample size considerations in genetic polymorphism studies. *Human Heredity*, **52**: 191–200.
- Buzdar, A.U., 2003. Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors. *Clinical Cancer Research*, **9**: 468s–472s.
- Campaign, J.A., 2004. Nicotine: potentially a multifunctional carcinogen? *Toxicological Sciences*, **79**: 1–3.
- Ceppa, F., Jahiri, Y.E., Mayaudon, H., Dupuy, O., and Burnat, P., 2000. High-performance liquid chromatographic determination of cotinine in urine in isocratic mode. *Journal of Chromatography B*, **746**: 115–22.
- Chenoweth, M.J., O'Loughlin, J., Sylvestre, M.-P., dan Tyndale, R.F., 2013. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. *Pharmacogenetics and Genomics*, **23**: 232–235.
- Chowdhury, G., Calcutt, M.W., dan Guengerich, F.P., 2010. Oxidation of N-Nitrosoalkylamines by human cytochrome P450 2A6: sequential oxidation to aldehydes and carboxylic acids and analysis of reaction steps. *The Journal of Biological Chemistry*, **285**: 8031–8044.
- Coleman, M.D., 2010. *Human Drug Metabolism: An Introduction*. John Wiley & Sons, hal. 23-28.
- Daigo, S., Takahashi, Y., Fujieda, M., Ariyoshi, N., Yamazaki, H., Koizumi, W., dkk., 2002. A novel mutant allele of the CYP2A6 gene (CYP2A6\*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. *Pharmacogenetics*, **12**: 299–306.



- Daly, A.K., King, B.P., dan Leathart, J.B.S., 2006. Genotyping for Cytochrome P450 Polymorphisms, dalam: Phillips, I.R. dan Shephard, E.A. (Editor), *Cytochrome P450 Protocols, Methods in Molecular Biology*. Humana Press, hal. 193–207.
- Dani, J.A. dan Heinemann, S., 1996. Molecular and cellular aspects of nicotine abuse. *Neuron*, **16**: 905–908.
- Derby, K.S., Cuthrell, K., Caberto, C., Carmella, S.G., Franke, A.A., Hecht, S.S., dkk., 2008. Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. *Cancer Epidemiology, Biomarkers & Prevention*, **17**: 3526–3535.
- Desta, Z., Kreutz, Y., Nguyen, A.T., Li, L., Skaar, T., Kamdem, L.K., dkk., 2011. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. *Clinical Pharmacology and Therapeutics*, **90**: 693–700.
- Di Iulio, J., Fayet, A., Arab-Alameddine, M., Rotger, M., Lubomirov, R., Cavassini, M., dkk., 2009. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. *Pharmacogenetics and Genomics*, **19**: 300–309.
- Ding, S., Lake, B.G., Friedberg, T., dan Wolf, C.R., 1995. Expression and alternative splicing of the cytochrome P-450 CYP2A7. *The Biochemical Journal*, **306** (Pt 1): 161–166.
- Djordjevic, N., Carrillo, J.A., Gervasini, G., Jankovic, S., dan Aklillu, E., 2010. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. *European Journal of Clinical Pharmacology*, **66**: 571–578.
- Doctor, P.B., Gokani, V.N., Kulkarni, P.K., Parikh, J.R., dan Saiyed, H.N., 2004. Determination of nicotine and cotinine in tobacco harvesters' urine by solid-phase extraction and liquid chromatography. *Journal of Chromatography B*, **802**: 323–328.
- Domino, E.F., 1999. Chapter 1 - Pharmacological significance of nicotine, dalam: Jacob, J.W.G. (Editor), *Analytical Determination of Nicotine and Related Compounds and Their Metabolites*. Elsevier Science, Amsterdam, hal. 1–11.



- Endo, T., Ban, M., Hirata, K., Yamamoto, A., Hara, Y., dan Momose, Y., 2007. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. *Drug Metabolism and Disposition*, **35**: 476–483.
- Endo, T., Nakajima, M., Fukami, T., Hara, Y., Hasunuma, T., Yokoi, T., dkk., 2008. Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine. *Pharmacogenetics and Genomics*, **18**: 761–772.
- F Ceppa, Y.E.J., 2000. High-performance liquid chromatographic determination of cotinine in urine in isocratic mode. *Journal of Chromatography B*, **746**: 115–22.
- Fernandez-Salguero, P. dan Gonzalez, F.J., 1995. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. *Pharmacogenetics*, **5 Spec No**: S123–128.
- Fernandez-Salguero, P., Hoffman, S.M., Cholerton, S., Mohrenweiser, H., Raunio, H., Rautio, A., dkk., 1995. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. *American Journal of Human Genetics*, **57**: 651–660.
- Fujieda, M., Yamazaki, H., Saito, T., Kiyotani, K., Gyamfi, M.A., Sakurai, M., dkk., 2004. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. *Carcinogenesis*, **25**: 2451–2458.
- Fukami, T., Nakajima, M., Yamanaka, H., Fukushima, Y., McLeod, H.L., dan Yokoi, T., 2007. A novel duplication type of CYP2A6 gene in African-American population. *Drug Metabolism and Disposition*, **35**: 515–520.
- Gambier, N., Batt, A.-M., Marie, B., Pfister, M., Siest, G., dan Visvikis-Siest, S., 2005. Association of CYP2A6\*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. *The Pharmacogenomics Journal*, **5**: 271–275.
- Guengerich, F.P., 2008. Cytochrome P450 and Chemical Toxicology. *Chemical Research in Toxicology*, **21**: 70–83.
- Gullstén, H., 2000. 'Significance of Polymorphism in CYP2A6 Gene', *Academic Dissertation*. Department of Pharmacology and Toxicology Universtiy of Oulu, Oulu.



- Gyllensten, U.B. dan Allen, M., 1993. Sequencing of in vitro amplified DNA, dalam: Wu, R. (Editor), *Methods in Enzymology, Recombinant DNA Part I*. Academic Press, hal. 3–16.
- Hannu Raunio, M.R.-R., 2012. CYP2A6: genetics, structure, regulation, and function. *Drug Metabolism and Drug Interactions*, **27**: 73–88.
- Hassanzadeh Khayyat, M., Vahdati Mashhadian, N., Eghbal, S., dan Jalali, N., 2013. Inter-individual Variability of Coumarin 7-hydroxylation (CYP2A6 activity) in an Iranian Population. *Iranian Journal of Basic Medical Sciences*, **16**: 610–614.
- Health, C. for H.P. and E.O. on S. and dan General, U.S.P.H.S.O. of the S., 1988. 'The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General', *Official reports, DHHS Publication No. (CDC) 88-8406*. URL: <http://profiles.nlm.nih.gov/NN/B/B/Z/D/> (diakses tanggal 17/12/2014).
- Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., dan Fagerström, K.O., 1991. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *British Journal of Addiction*, **86**: 1119–1127.
- Hecht, S.S., 2003. Tobacco Carcinogens, Their Biomarkers and Tobacco-Induced cancer. *Nature Reviews Cancer*, **3**: 733–744.
- Hecht, S.S., 2012. Lung Carcinogenesis by Tobacco Smoke. *International Journal of Cancer.*, **131**: 2724–2732.
- Hecht, S.S. dan Tricker, A.R., 1999. Chapter 11 - Nitrosamines derived from nicotine and other tobacco alkaloids, dalam: Jacob, J.W.G. (Editor), *Analytical Determination of Nicotine and Related Compounds and Their Metabolites*. Elsevier Science, Amsterdam, hal. 421–488.
- Henningfield, J.E. dan Keenan, R.M., 1993. Nicotine delivery kinetics and abuse liability. *Journal of Consulting and Clinical Psychology*, **61**: 743–750.
- Henningfield, J.E., London, E., dan Pogun, S., 2009. *Nicotine Psychopharmacology*. Springer, hal. 30-31.
- Henningfield, J.E., Stapleton, J.M., Benowitz, N.L., Grayson, R.F., dan London, E.D., 1993. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. *Drug and Alcohol Dependence*, **33**: 23–29.



- Heravi, R.E., Ramezani, M., dan Behravan, J., 2010. Association Between Nicotine Metabolism and *CYP2A6\*1* and *CYP2A6\*4* Genotypes in an Iranian Population. *DNA and Cell Biology*, **29**: 369–373.
- Hidayah, Z., 1997. *Ensiklopedi: Suku bangsa di Indonesia*. Pustaka LP3ES.
- Ho, M.K., Mwenifumbo, J.C., Al Koudsi, N., Okuyemi, K.S., Ahluwalia, J.S., Benowitz, N.L., dkk., 2009. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. *Clinical Pharmacology and Therapeutics*, **85**: 635–643.
- Howard, L.A., Miksys, S., Hoffmann, E., Mash, D., dan Tyndale, R.F., 2003. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. *British Journal of Pharmacology*, **138**: 1376–1386.
- Hukkanen, J., Jacob, P., 3rd, dan Benowitz, N.L., 2005. Metabolism and disposition kinetics of nicotine. *Pharmacological Reviews*, **57**: 79–115.
- Ikeda, K., Yoshisue, K., Matsushima, E., Nagayama, S., Kobayashi, K., Tyson, C.A., dkk., 2000. Bioactivation of Tegafur to 5-Fluorouracil Is Catalyzed by Cytochrome P-450 2A6 in Human Liver Microsomes in Vitro. *Clinical Cancer Research*, **6**: 4409–4415.
- Ingelman-Sundberg, M., Oscarson, M., Daly, A.K., Garte, S., dan Nebert, D.W., 2001. Human Cytochrome P-450 (CYP) Genes A Web Page for the Nomenclature of Alleles. *Cancer Epidemiology Biomarkers & Prevention*, **10**: 1307–1308.
- Ioannides, C., 2008. *Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and Other Xenobiotics*. Royal Society of Chemistry, hal. 159.
- Islam, M.S., Ahmed, M.U., Sayeed, M.S.B., Maruf, A.A., Mostofa, A.G.M., Hussain, S.M.A., dkk., 2013. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladesh population. *Clinica Chimica Acta*, **416**: 11–19.
- Jacob, N., Berny, C., Boyer, J.-C., Capolaghi, B., de L’Homme, G., Desch, G., dkk., 2005. Urinary cotinine and nicotine metabolites measurement. *Annales de Biologie Clinique*, **63**: 397–409.



- Jacob, P., 3rd, Yu, L., Duan, M., Ramos, L., Yturalde, O., dan Benowitz, N.L., 2011. Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. *Journal of Chromatography B*, **879**: 267–276.
- Jensen, K., Afroze, S., Munshi, M.K., Guerrier, M., dan Glaser, S.S., 2012. Mechanisms for nicotine in the development and progression of gastrointestinal cancers. *Translational Gastrointestinal Cancer*, **1**: 81–87.
- Jeong, S., Woo, M.M., Flockhart, D.A., dan Desta, Z., 2009. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. *Cancer Chemotherapy and Pharmacology*, **64**: 867–875.
- Jiloha, R.C., 2008. *Tobacco use: Health and behavior*. New Age International, New Delhi, **50**: 129–137.
- Johnstone, E., Benowitz, N., Cargill, A., Jacob, R., Hinks, L., Day, I., dkk., 2006. Determinants of the rate of nicotine metabolism and effects on smoking behavior. *Clinical Pharmacology and Therapeutics*, **80**: 319–330.
- Kadlubar, S., Anderson, J.P., Sweeney, C., Gross, M.D., Lang, N.P., Kadlubar, F.F., dkk., 2009. Phenotypic CYP2A6 variation and the risk of pancreatic cancer. *JOP: Journal of the Pancreas*, **10**: 263–270.
- Kamataki, T., 2006. Genetic Polymorphism of CYP2A6 and Tobacco-Related Cancer Risk: From the Establishment of Genetically Engineered Salmonella to Large Scale Epidemiology. *Genes and Environment*, **28**: 77–83.
- Kamataki, T., Fujita, K., Nakayama, K., Yamazaki, Y., Miyamoto, M., dan Ariyoshi, N., 2002. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. *Drug Metabolism Reviews*, **34**: 667–676.
- Karaconji, I.B., 2005. Facts about nicotine toxicity. *Arhiv za Higijenu Rada i Toksikologiju*, **56**: 363–371.
- Kim, D., Wu, Z.-L., dan Guengerich, F.P., 2005. Analysis of Coumarin 7-Hydroxylation Activity of Cytochrome P450 2A6 using Random Mutagenesis. *Journal of Biological Chemistry*, **280**: 40319–40327.



- Kim, I., Wtsadik, A., Choo, R.E., Jones, H.E., dan Huestis, M.A., 2005. Usefulness of salivary trans-3'-hydroxycotinine concentration and trans-3'-hydroxycotinine/cotinine ratio as biomarkers of cigarette smoke in pregnant women. *Journal of Analytical Toxicology*, **29**: 689–695.
- Kimura, M., Yamazaki, H., Fujieda, M., Kiyotani, K., Honda, G., Saruwatari, J., dkk., 2005. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. *Drug Metabolism and Disposition*, **33**: 1361–1366.
- Kwon, J.T., Nakajima, M., Chai, S., Yom, Y.K., Kim, H.K., Yamazaki, H., dkk., 2001. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. *Pharmacogenetics*, **11**: 317–323.
- Kosen S, Hardjo H, Kadarmanto, Sinha D N, Palipudi K M, Wibisana W, dkk., 2012. *Global Adult Tobacco Survey: Indonesia Report 2011*. National Institute of Health Research and Development, Jakarta Indonesia, hal. 1-2.
- Kubota, T., Nakajima-Taniguchi, C., Fukuda, T., Funamoto, M., Maeda, M., Tange, E., dkk., 2006. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. *The Pharmacogenomics Journal*, **6**: 115–119.
- Kwon, J.T., Nakajima, M., Chai, S., Yom, Y.K., Kim, H.K., Yamazaki, H., dkk., 2001. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. *Pharmacogenetics*, **11**: 317–323.
- Lea, R., Benowitz, N., Green, M., Fowles, J., Vishvanath, A., Dickson, S., dkk., 2005. Ethnic differences in nicotine metabolic rate among New Zealanders. *The New Zealand Medical Journal*, **118**: U1773.
- Lian, T.Y., Dorotheo, U., 2014. *The ASEAN Tobacco Control Atlas*, 2<sup>st</sup> Ed. Southeast Asia Tobacco Control Alliance (SEATCA), Bangkok.
- Liu, T., David, S.P., Tyndale, R.F., Wang, H., Zhou, Q., Ding, P., dkk., 2011. Associations of CYP2A6 genotype with smoking behaviors in southern China. *Addiction*, **106**: 985–994.
- Liu, T., Xie, C.-B., Ma, W.-J., dan Chen, W.-Q., 2013. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. *Environmental and Molecular Mutagenesis*, **54**: 133–140.



- Liu, Y., Xu, Y., Li, F., Chen, H., dan Guo, S., 2013. CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. *Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine*, **34**: 2651–2657.
- Malaiyandi, V., Goodz, S.D., Sellers, E.M., dan Tyndale, R.F., 2006. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. *Cancer Epidemiology, Biomarkers & Prevention*, **15**: 1812–1819.
- Malaiyandi, V., Lerman, C., Benowitz, N.L., Jepson, C., Patterson, F., dan Tyndale, R.F., 2006. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. *Molecular Psychiatry*, **11**: 400–409.
- Mallery, S.R., Tong, M., Michaels, G.C., Kiyani, A.R., dan Hecht, S.S., 2014. Clinical and Biochemical Studies Support Smokeless Tobacco's Carcinogenic Potential in the Human Oral Cavity. *Cancer Prevention Research*, **7**: 23–32.
- Man, C.N., Gam, L.-H., Ismail, S., Lajis, R., dan Awang, R., 2006. Simple, rapid and sensitive assay method for simultaneous quantification of urinary nicotine and cotinine using gas chromatography-mass spectrometry. *Journal of Chromatography B*, **844**: 322–327.
- Martini, S., 2014. Makna Merokok pada Remaja Putri Perokok. *Jurnal Psikologi Pendidikan dan Perkembangan*. Fakultas Psikologi Universitas Airlangga, **3** (2): 119-127.
- Massadeh, A.M., Gharaibeh, A.A., dan Omari, K.W., 2009. A single-step extraction method for the determination of nicotine and cotinine in Jordanian smokers' blood and urine samples by RP-HPLC and GC-MS. *Journal of Chromatographic Science*, **47**: 170–177.
- Matt, G.E., Quintana, P.J.E., Liles, S., Hovell, M.F., Zakarian, J.M., Jacob, P., 3rd, dkk., 2006. Evaluation of urinary trans-3'-hydroxycotinine as a biomarker of children's environmental tobacco smoke exposure. *Biomarkers*, **11**: 507–523.
- McPherson, M.J. dan Moller, S.G., 2006. *PCR*, 2 edition. ed. Taylor & Francis, New York, hal. 26, 65-75.



- Meger, M., Meger-Kossien, I., Schuler-Metz, A., Janket, D., dan Scherer, G., 2002. Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B*, **778**: 251–261.
- Mendelsohn, C.P., 2011. Mendelsohn C. Nicotine dependence: Why is it so hard to quit?. *Medicine Today*, **12**: 35–40.
- Miles, J.S., Bickmore, W., Brook, J.D., McLaren, A.W., Meehan, R., dan Wolf, C.R., 1989. Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity. *Nucleic Acids Research*, **17**: 2907–2917.
- Miles, J.S., McLaren, A.W., Forrester, L.M., Glancey, M.J., Lang, M.A., dan Wolf, C.R., 1990. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. *The Biochemical Journal*, **267**: 365–371.
- Minematsu, N., Nakamura, H., Furuuchi, M., Nakajima, T., Takahashi, S., Tateno, H., dkk., 2006. Limitation of cigarette consumption by CYP2A6\*4, \*7 and \*9 polymorphisms. *The European Respiratory Journal*, **27**: 289–292.
- Minematsu, N., Nakamura, H., Iwata, M., Tateno, H., Nakajima, T., Takahashi, S., dkk., 2003. Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. *Thorax*, **58**: 623–628.
- Munafò, M., Clark, T., Johnstone, E., Murphy, M., dan Walton, R., 2004. The genetic basis for smoking behavior: a systematic review and meta-analysis. *Nicotine & Tobacco Research*, **6**: 583–597.
- Muroi, A., Kiyotani, K., Fujieda, M., Ishikawa, H., Takeshi, T., Iwano, S., dkk., 2012. Effect of Genetic Polymorphism of CYP2A6 on Individual Susceptibility to Colorectal Tumors in Japanese Smokers. *Journal of Cancer Therapy*, **3**: 207–215.
- Murray, R., Rodwell, V., Bender, D., Botham, K.M., Weil, P.A., dan Kennelly, P.J., 2009. *Harper's Illustrated Biochemistry, 28th Edition*. McGraw Hill Professional.
- Mwenifumbo, J.C., Al Koudsi, N., Ho, M.K., Zhou, Q., Hoffmann, E.B., Sellers, E.M., dkk., 2008. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. *Human Mutation*, **29**: 679–688.



- Mwenifumbo, J.C., Zhou, Q., Benowitz, N.L., Sellers, E.M., dan Tyndale, R.F., 2010. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. *Pharmacogenomics*, **11**: 189–198.
- Nagano, T., Shimizu, M., Kiyotani, K., Kamataki, T., Takano, R., Murayama, N., dkk., 2010. Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population. *International Journal of Environmental Research and Public Health*, **7**: 2953–2964.
- Nakajima, M., Fukami, T., Yamanaka, H., Higashi, E., Sakai, H., Yoshida, R., dkk., 2006. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. *Clinical Pharmacology and Therapeutics*, **80**: 282–297.
- Nakajima, M., Kwon, J.T., Tanaka, N., Zenta, T., Yamamoto, Y., Yamamoto, H., dkk., 2001. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. *Clinical Pharmacology and Therapeutics*, **69**: 72–78.
- Nakajima, M., Tanaka, E., Kwon, J.-T., dan Yokoi, T., 2002. Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. *Drug Metabolism and Disposition*, **30**: 1484–1490.
- Nakajima, M., Yamagishi, S., Yamamoto, H., Yamamoto, T., Kuroiwa, Y., dan Yokoi, T., 2000. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. *Clinical Pharmacology and Therapeutics*, **67**: 57–69.
- Nakajima, M. dan Yokoi, T., 2005. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. *Drug Metabolism and Pharmacokinetics*, **20**: 227–235.
- Nakajima, M., Yoshida, R., Fukami, T., McLeod, H.L., dan Yokoi, T., 2004. Novel human CYP2A6 alleles confound gene deletion analysis. *FEBS letters*, **569**: 75–81.
- Nelson, D.R., Koymans, L., Kamataki, T., Stegeman, J.J., Feyereisen, R., Waxman, D.J., dkk., 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics*, **6**: 1–42.



- Nowell, S., Sweeney, C., Hammons, G., Kadlubar, F.F., dan Lang, N.P., 2002. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. *Cancer Epidemiology, Biomarkers & Prevention*, **11**: 377–383.
- Nunoya, K.I., Yokoi, T., Kimura, K., Kainuma, T., Satoh, K., Kinoshita, M., dkk., 1999. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. *The Journal of Pharmacology and Experimental Therapeutics*, **289**: 437–442.
- O’Loughlin, J., Paradis, G., Kim, W., DiFranza, J., Meshefedjian, G., McMillan-Davey, E., dkk., 2004. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. *Tobacco Control*, **13**: 422–428.
- Organization, W.H., Iarc, dan Who, 1986. *Vol 38 IARC Monographs: Tobacco Smoking*. World Health Organization, Lyon.
- Oscarson, M., 2001. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. *Drug Metabolism and Disposition*, **29**: 91–95.
- Oscarson, M., Gullstén, H., Rautio, A., Bernal, M.L., Sinues, B., Dahl, M.L., dkk., 1998. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. *FEBS letters*, **438**: 201–205.
- Oscarson, M., McLellan, R.A., Gullstén, H., Agúndez, J.A., Benítez, J., Rautio, A., dkk., 1999. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. *FEBS letters*, **460**: 321–327.
- Otmar, G. dan Dimitrios, K., 2007. *Tobacco, Cigarettes and Cigarette Smoke - An Overview*. European Communities, Italy.
- Page-Sharp, M., Hale, T.W., Hackett, L.P., Kristensen, J.H., dan Ilett, K.F., 2003. Measurement of nicotine and cotinine in human milk by high-performance liquid chromatography with ultraviolet absorbance detection. *Journal of Chromatography B*, **796**: 173–180.



- Patramurti, C., Sudibyo, M., Nurrochmad, A., Sugiyanto, 2014. Optimasi Metode Kromatografi Cair Kinerja Tinggi menggunakan Kolom Oktil Silika *Fully Endcapped Residual Silanol* pada Pemisahan Kotinin dan 3-Hidroksikotinin dalam Sampel Urin. *JIFI*, 12 (1), 110-116
- Peamkrasatam, S., Sriwatanakul, K., Kiyotani, K., Fujieda, M., Yamazaki, H., Kamataki, T., dkk., 2006. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. *Drug Metabolism and Pharmacokinetics*, **21**: 475–484.
- Pelkonen, O., Raunio, H., Rautio, A., dan Lang, M., 1999. Xenobiotic-metabolizing enzymes and cancer risk: correspondence between genotype and phenotype. *IARC Scientific Publications*, 77–88.
- Petrus, A. 2012. Kondisi Fisik, Wilayah dan Penduduk Indonesia , diakses tanggal 19 Januari 21015. <<https://abelpetrus.wordpress.com/geography/kondisi-fisik-wilayah-dan-penduduk-indonesia/>>.
- Pianezza, M.L., Sellers, E.M., dan Tyndale, R.F., 1998. Nicotine metabolism defect reduces smoking. *Nature*, **393**: 750.
- Piller, M., Gilch, G., Scherer, G., dan Scherer, M., 2014. Simple, fast and sensitive LC-MS/MS analysis for the simultaneous quantification of nicotine and 10 of its major metabolites. *Journal of Chromatography B*, **951-952**: 7–15.
- Puliyappadamba, V.T., Cheriyan, V.T., Thulasidasan, A.K.T., Bava, S.V., Vinod, B.S., Prabhu, P.R., dkk., 2010. Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. *Molecular Cancer*, **9**: 220-235.
- Rabbaa-Khabbaz, L., Abi Daoud, R., dan Karam-Sarkis, D., 2006. A simple, sensitive, and rapid method for the determination of cotinine in urine by high-performance liquid chromatography with UV detection. *Journal of Chromatographic Science*, **44**: 535–538.
- Rao, Y., Hoffmann, E., Zia, M., Bodin, L., Zeman, M., Sellers, E.M., dkk., 2000. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. *Molecular Pharmacology*, **58**: 747–755.



- Raunio, H., Rautio, A., Gullstén, H., dan Pelkonen, O., 2001. Polymorphisms of CYP2A6 and its practical consequences. *British Journal of Clinical Pharmacology*, **52**: 357–363.
- Rautio, A., 2003. Polymorphic CYP2A6 and its clinical and toxicological significance. *The Pharmacogenomics Journal*, **3**: 5–7.
- Ray, R., Tyndale, R.F., dan Lerman, C., 2009. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. *Journal of Neurogenetics*, **23**: 252–261.
- Rodgman, A. dan Perfetti, T.A., 2008. *The Chemical Components of Tobacco and Tobacco Smoke*. CRC Press, hal. 1-3.
- Rubinstein, M.L., Benowitz, N.L., Auerback, G.M., dan Moscicki, A.-B., 2008. Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. *Pediatrics*, **122**: e643–647.
- Schoedel, K.A., Hoffmann, E.B., Rao, Y., Sellers, E.M., dan Tyndale, R.F., 2004. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. *Pharmacogenetics*, **14**: 615–626.
- Shakleya, D.M. dan Huestis, M.A., 2009. Simultaneous and sensitive measurement of nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B*, **877**: 3537–3542.
- Shields, P.G., 2002. Molecular epidemiology of smoking and lung cancer. *Oncogene*, **21**: 6870–6876.
- Shin, H.-S., Kim, J.-G., Shin, Y.-J., dan Jee, S.H., 2002. Sensitive and simple method for the determination of nicotine and cotinine in human urine, plasma and saliva by gas chromatography-mass spectrometry. *Journal of Chromatography B*, **769**: 177–183.
- Shows, T.B., McAlpine, P.J., Boucheix, C., Collins, F.S., Conneally, P.M., Frézal, J., dkk., 1987. Guidelines for human gene nomenclature. An international system for human gene nomenclature (ISGN, 1987). *Cytogenetics and Cell Genetics*, **46**: 11–28.
- Singh, S., Pillai, S., dan Chellappan, S., 2011. Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. *Journal of Oncology*, **11**: 1-11.



- Snyder, L.R., Kirkland, J.J., dan Dolan, J.W., 2011. *Introduction to Modern Liquid Chromatography*. John Wiley & Sons, hal.33-34, 231, 228.
- St Helen, G., Novalen, M., Heitjan, D.F., Dempsey, D., Jacob, P., 3rd, Aziziyeh, A., dkk., 2012. Reproducibility of the nicotine metabolite ratio in cigarette smokers. *Cancer Epidemiology, Biomarkers & Prevention*, **21**: 1105–1114.
- Strasser, A.A., Benowitz, N.L., Pinto, A.G., Tang, K.Z., Hecht, S.S., Carmella, S.G., dkk., 2011. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. *Cancer Epidemiology, Biomarkers & Prevention*, **20**: 234–238.
- Swan, G.E., Baker T B, Chassin L, Conti D V, Lerman C, dan Perkins K A, 2009. *Phenotypes and Endophenotypes: Foundations for Genetic Studies of Nicotine Use and Dependence : Executive Summary*. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, hal. 562-563.
- Tandilittin, H. dan Luetge, C., 2013. Civil Society and Tobacco Control in Indonesia: The Last Resort. *Open Ethics Journal*, **7**: 11–18.
- Tan, L., Yu, J.-T., Sun, Y.-P., Ou, J.-R., Song, J.-H., dan Yu, Y., 2010. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. *Clinical Neurology and Neurosurgery*, **112**: 320–323.
- Tan, W., Chen, G.F., Xing, D.Y., Song, C.Y., Kadlubar, F.F., dan Lin, D.X., 2001. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. *International Journal of Cancer*, **95**: 96–101.
- Topcu, Z., Chiba, I., Fujieda, M., Shibata, T., Ariyoshi, N., Yamazaki, H., dkk., 2002. CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. *Carcinogenesis*, **23**: 595–598.
- Trihandini, R.A.F.M. dan Wismanto, Y.B., 2003. Perilaku Merokok Mahasiswi Ditinjau dari Persepsi terhadap Gaya Hidup Modern. *Skripsi*. Semarang: Fakultas Psikologi-Universitas Katolik Soegijapranata.
- Tutka, P., Mosiewicz, J., dan Wielosz, M., 2005. Pharmacokinetics and metabolism of nicotine. *Pharmacological reports: PR*, **57**: 143–153.



- Tyndale, R.F. dan Sellers, E.M., 2002. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. *Therapeutic Drug Monitoring*, **24**: 163–171.
- Tyrpień, K., Wielkoszyński, T., Janoszka, B., Dobosz, C., Bodzek, D., dan Steplewski, Z., 2000. Application of liquid separation techniques to the determination of the main urinary nicotine metabolites. *Journal of Chromatography A*, **870**: 29–38.
- Universitas Gadjah Mada, 2007. *Indonesia termasuk 5 Negara dengan Konsumsi Rokok Terbesar di Dunia*, diakses tanggal 6/2/2015, <<http://ugm.ac.id/id/berita/908-indonesia.termasuk.5.negara.dengan.konsumsi.rokok.terbesar.di.dunia>>.
- U.S. Departement of Health and Human Services, 2001. *Guidance for Industry Bioanalytical Method Validation*. FDA, Center for Drug Evaluation and Research (CDER), Rockville, MD.
- U.S. Department of Health and Human Services, 2010. *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General*. Public Health Service, Office of the Surgeon General, Rockville, MD.
- Wang, L., Zang, W., Liu, J., Xie, D., Ji, W., Pan, Y., dkk., 2013. Association of CYP2A6\*4 with susceptibility of lung cancer: a meta-analysis. *PloS one*, **8**: e59556.
- Wen, Y.-H., Yang, P.-S., dan Wu, S.-S., 2009. Determination of Cotinine in Human Urine by High-Performance Liquid Chromatography. *Journal of Food and Drug Analysis*, **17**: 357–362.
- West, O., Hajek, P., dan McRobbie, H., 2011. Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. *Psychopharmacology*, **218**: 313–322.
- Weymarn, L.B. von, Retzlaff, C., dan Murphy, S.E., 2012. CYP2A6- and CYP2A13-Catalyzed Metabolism of the Nicotine  $\Delta 5'(1')$ Iminium Ion. *Journal of Pharmacology and Experimental Therapeutics*, **343**: 307–315.
- World Health Organization. 2008, *WHO Report on the Global Tobacco Epidemic 2008*, diakses tanggal 21/11/2014), <[http://www.who.int/tobacco/mpower/gtr\\_download/en/](http://www.who.int/tobacco/mpower/gtr_download/en/)>.



- World Health Organization. 2013, *WHO report on the global tobacco epidemic 2013*, diakses tanggal 21/11/2014, <[http://www.who.int/tobacco/global\\_report/2013/en/](http://www.who.int/tobacco/global_report/2013/en/)>.
- Wismanto, Y.B. dan Sarwo, Y.B., 2007, *Strategi Penghentian Perilaku Merokok*, Unika Soegijapranata, Semarang.
- Xu, P., Huang, S.-L., Zhu, R.-H., Han, X.-M., dan Zhou, H.-H., 2002. Phenotypic polymorphism of CYP2A6 activity in a Chinese population. *European Journal of Clinical Pharmacology*, **58**: 333–337.
- Xu, X., Iba, M.M., dan Weisel, C.P., 2004. Simultaneous and sensitive measurement of anabasine, nicotine, and nicotine metabolites in human urine by liquid chromatography-tandem mass spectrometry. *Clinical Chemistry*, **50**: 2323–2330.
- Yamanaka, H., Nakajima, M., Nishimura, K., Yoshida, R., Fukami, T., Katoh, M., dkk., 2004. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. *European Journal of Pharmaceutical Sciences*, **22**: 419–425.
- Yamazaki, H., Inoue, K., Hashimoto, M., dan Shimada, T., 1999. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. *Archives of Toxicology*, **73**: 65–70.
- Yang, M., Kunugita, N., Kitagawa, K., Kang, S.H., Coles, B., Kadlubar, F.F., dkk., 2001. Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. *Cancer Epidemiology, Biomarkers & Prevention*, **10**: 589–593.
- Yildiz, D., 2004. Nicotine, its metabolism and an overview of its biological effects. *Toxicol*, **43**: 619–632.
- Yoshida, R., Nakajima, M., Nishimura, K., Tokudome, S., Kwon, J.-T., dan Yokoi, T., 2003. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6\*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. *Clinical Pharmacology and Therapeutics*, **74**: 69–76.
- Yusof, W. dan Gan, S.H., 2009. High prevalence of CYP2A6\*4 and CYP2A6\*9 alleles detected among a Malaysian population. *Clinica Chimica Acta*, **403**: 105–109.